Abstract:Myelin loss induces deficits in action potential propagation that result in neural dysfunction and contribute to the pathophysiology of neurodegenerative diseases, injury conditions, and aging. Because remyelination is often incomplete, better understanding endogenous remyelination and developing remyelination therapies that seek to restore neural function are clinical imperatives. Here, we used two-photon microscopy and electrophysiology to study the dynamics of endogenous and therapeutic-induced cortical remyelination and functional recovery after cuprizone-mediated demyelination in mice. We focused on the visual pathway, which is uniquely positioned to provide insights into structure-function relationships during de/remyelination. We show that endogenous remyelination is driven by recent oligodendrocyte loss and is highly efficacious following mild demyelination, but fails to restore the oligodendrocyte population when high rates of oligodendrocyte loss occur too quickly. Testing a novel thyromimetic compared to clemastine fumarate, we find it better enhances oligodendrocyte gain during remyelination and hastens recovery of neuronal function. Surprisingly, its therapeutic benefit was temporally restricted, and it acted exclusively following moderate to severe demyelination to eliminate endogenous remyelination deficits. However, complete remyelination is unnecessary as partial oligodendrocyte restoration was sufficient to recover visual neuronal function. These findings advance our understanding of remyelination and its impact on functional recovery to inform future therapeutic strategies.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is: how to restore visual cortex function in the case of incomplete remyelination by enhancing endogenous or therapeutically - induced oligodendrogenesis. Specifically, the researchers focused on the following aspects: 1. **Effects of myelin loss**: Myelin loss can lead to a delay in action potential propagation, which in turn causes neurological dysfunction. This is manifested in various neurodegenerative diseases, injury conditions and aging. Therefore, understanding the endogenous remyelination mechanism and its limitations, and developing effective remyelination therapies are of great significance for restoring neurological function. 2. **Dynamic processes of endogenous and therapeutic remyelination**: The researchers used in vivo two - photon microscopy and electrophysiological methods to study the dynamic processes of endogenous and therapeutically - induced cortical remyelination and functional recovery in mice after cuprizone - induced demyelination. They paid special attention to the visual pathway because it can provide unique insights into the structure - function relationship during the demyelination/remyelination process. 3. **Effects of a new thyroid hormone analogue**: The researchers tested the effects of a new thyroid hormone analogue (LL - 341070) compared with known drugs (such as clemastine fumarate) in promoting oligodendrogenesis and accelerating the recovery of neurological function. The results showed that LL - 341070 can increase the number of oligodendrocytes more rapidly and effectively, especially after moderate to severe demyelination, and can eliminate the deficiency of endogenous remyelination. 4. **Sufficiency of partial remyelination**: The study found that even without complete remyelination, the restoration of some oligodendrocytes is sufficient to restore the function of visual neurons. This finding has important guiding significance for future remyelination treatment strategies. In summary, this paper aims to provide theoretical basis and technical support for the development of effective remyelination therapies by in - depth exploration of the mechanisms of endogenous and therapeutic remyelination and their effects on the recovery of neurological function.

Incomplete remyelination via endogenous or therapeutically enhanced oligodendrogenesis is sufficient to recover visual cortical function

Remyelination in the CNS: from biology to therapy

[Neuroscience] Remyelination in the Central Nervous System

Monitoring recovery after CNS demyelination, a novel tool to de-risk pro-remyelinating strategies

Accelerated Remyelination During Inflammatory Demyelination Prevents Axonal Loss and Improves Functional Recovery

Validating visual evoked potentials as a preclinical, quantitative biomarker for remyelination efficacy

Preventing production of new oligodendrocytes impairs remyelination and sustains behavioural deficits after demyelination

Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials

Remyelination reporter reveals prolonged refinement of spontaneously regenerated myelin

The Study of Remyelinating Therapies in Multiple Sclerosis: Visual Outcomes as a Window Into Repair

Remyelinating Drugs at a Crossroad: How to Improve Clinical Efficacy and Drug Screenings

Remyelinating Pharmacotherapies in Multiple Sclerosis

Remyelination protects neurons from DLK-mediated neurodegeneration

Cell-based remyelinating therapy in inflammatory demyelinating injury of the CNS

Multimodal Enhancement of Remyelination by Exercise with a Pivotal Role for Oligodendroglial PGC1α

Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches

Endogenous Nkx2.2+/Olig2+ oligodendrocyte precursor cells fail to remyelinate the demyelinated adult rat spinal cord in the absence of astrocytes

The dynamics of oligodendrocyte populations following permanent ischemia promotes long-term spontaneous remyelination of damaged area

Regenerative Capacity of Macrophages for Remyelination

Remyelination in Neuromyelitis Optica Spectrum Disorder is Promoted by Edaravone Through Mtorc1 Signaling Activation.

Pharmacological treatment promoting remyelination enhances motor function after internal capsule demyelination in mice